ePharmaSolutions' ReferralPlus Increases Match Rate For Clinical Trial Volunteers By More than 66%
ePharmaSolutions, a provider of eClinical solutions, announced positive results of initial pilot studies for its patient matching and triaging solution, ReferralPlus.
ePharmaSolutions, a provider of eClinical solutions, announced positive results of initial pilot studies for its patient matching and triaging solution, ReferralPlus™. ReferralPlus™ was designed by ePharmaSolutions as a tool to match patients who disqualify for one study with others they might qualify for using a geo-therapeutic matching algorithm with other studies listed on their technology.
In 2012, ePharmaSolutions organized more than 30 major pharmaceutical companies and CROs to participate in the pilots to determine if they could help increase enrollment rates by triaging/matching patients who disqualified from one clinical trial to trials listed by other participating sponsors. The pilots started at the end of 2013 with the early results showing a significant improvement in cross-study matching which will offer significant economic advantages to pharmaceutical companies recruiting patients while providing patients with more opportunities to find for the right study.
The pilot data came from three pharmaceutical companies who listed their studies on the CenterWatch™ web listing service and used the ReferralPlus™ screening and matching solution. None of the pilot studies included an advertising outreach budget.
The results are summarized below:
- 33% of the total patients who screened for one study were eligible for and referred to a study site
- 18% of patients who disqualified from the first study, pre-qualified and were referred to another study
- 50% of patients who disqualified for any of the studies listed, registered to be contacted about future studies
Read the full release here.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
